Hy-Tech Engineers has achieved exceptional performance on the final day of bidding, with the IPO closing at 244.41 times subscription by 17:30 pm on August 27. The issue received bids for 443.49 crore shares against 1.84 crore shares on offer, with the QIB portion subscribed 255.77 times and NII portion showing remarkable demand at 402.29 times. The retail portion demonstrated strong investor interest with 170.58 times subscription, receiving bids for 81.64 crore shares against 92.01 lakh shares reserved. As per Business Standard, the issue opened for bidding on August 24 and closed on August 27, with the price band fixed between ₹50-₹53 per share and a minimum bid requirement of 283 equity shares. The allotment is expected to be finalised today, with shares likely to debut on NSE and BSE on September 1, 2026.
The latest data shows Hy-Tech Engineers leading with the highest subscription rate of 244.41 times, significantly outperforming Tempsens Instruments at 184.07 times. According to Live Mint, the strong demand for Hy-Tech Engineers was led by non-institutional investors (NIIs) whose portion was subscribed 412 times, followed by retail investors at 175 times and qualified institutional buyers (QIBs) at 249 times. In contrast, the Tempsens Instruments IPO saw the non-institutional investor segment subscribed 314.44 times and QIB portion receiving bids for 302.88 times the shares on offer. The retail individual investor (RII) quota was subscribed 60.69 times, reflecting robust participation across all investor categories. The grey market premiums provide additional context, with Hy-Tech Engineers maintaining the highest GMP of ₹45, indicating an estimated listing price of around ₹97 which is 83.02% higher than the IPO price of ₹53. Tempsens Instruments commands a GMP of ₹307, suggesting an estimated listing price of around ₹607 per share, indicating a potential premium of approximately 102.33% over the IPO price.
Hy-Tech Engineers is a mainboard issue worth ₹135.73 crore, comprising a fresh issue of ₹60 crore and an offer-for-sale of ₹75.73 crore. The company has proposed to utilize ₹29.96 crore from net proceeds towards procurement of machinery and equipment for expansion at Kavathe Unit, Shirwal Unit and Pithampur Unit-I, while ₹16 crore will be used for loan repayment. The entire offer for sale comprises 1.42 crore shares worth ₹75.73 crore, with the entire OFS being by promoters. The company had raised ₹40.72 crore from anchor investors ahead of the issue, with the board allotting 76.83 lakh shares at ₹53 each to 8 anchor investors. Tempsens Instruments raised ₹650 crore through its IPO, comprising a fresh issue of 32 lakh shares worth ₹95 crore and an OFS of 1.85 crore shares worth ₹555 crore.
Hy-Tech Engineers operates across diverse industrial applications including construction machinery, automotive, farming machinery, injection moulding machines and hydraulic systems. The company has obtained certification enabling it to serve railways and defence sectors, expanding its addressable market. In FY26, construction machinery contributed 22.94% to sales, followed by farming at 22.83%, automotive at 9.05%, hydraulic systems at 5.09%, injection moulding machines at 3.98%, IPE & Railways at 1.45% and parking systems at 0.29%, while other segments accounted for 34.37%. Domestic sales contributed 70.63% of revenue compared to 71.70% in FY25, while overseas sales accounted for 29.37%, up from 28.30% in FY25. The company reported a consolidated net profit of ₹22.59 crore and sales of ₹189.40 crore for the twelve months ended March 31, 2026. Post-expansion, the estimated installed capacity at Shirwal, Pithampur Unit-I and Kavathe is expected to increase by 45.00%, 83.08% and 41.25% respectively, subject to timely commissioning.
The current GMP trends indicate positive sentiment across both IPOs. Hy-Tech Engineers maintains the highest GMP of ₹45 (₹45 or ₹45%) suggesting an estimated listing price of around ₹97, which is 83.02% higher than the IPO price of ₹53. As per Live Mint, the GMP has been rising today and fluctuated between ₹5 and ₹44 over the past nine sessions, indicating improving sentiment towards its potential market debut. Tempsens Instruments commands a GMP of ₹307, indicating an estimated listing price of around ₹607 per share, which is 102.33% higher than the IPO price of ₹300. The pharma and biotech company's GMP has fluctuated between ₹220 and ₹410 over the past nine sessions. However, grey market premiums are unofficial indicators and can change before listing, they do not guarantee actual listing price or returns. The strong participation across investor categories in both IPOs reflects continued enthusiasm for new market offerings and robust investor appetite for primary market opportunities.
